1 completed, 1 unknown. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow M.H.H. Kramer: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22) - Type2 Diabetes | Phase 4 | Unknown | M.H.H. Kramer | 66 | 2017-11-09 | 2022-01-14 |
| Renoprotective Effects of Dapagliflozin in Type 2 Diabetes Dapagliflozin 10mg QD, Gliclazide 30mg QD - Diabetes Mellitus, Type 2, Diabetic Nephropathies | Phase 4 | Completed | M.H.H. Kramer | 44 | 2016-02-01 | 2020-07-07 |
Diabetes Mellitus, Type 2 (2) · Diabetic Nephropathies (2)
Gliclazide (2) · Linagliptin (1) · dapagliflozin (1) · empagliflozin (1)
Netherlands (2)
Mark HH Kramer, MD PhD (1) · Mark HH Kramer, MD/PhD (1)
PMID 31816432, PMID 32200854, PMID 32516291, PMID 33205810, PMID 35221224, PMID 35322793, PMID 38770818, PMID 41665872
2015 (1)